A Phase 1 Study to Evaluate OP-1 (SB0405) Injected into One Lumbar Intervertebral Disc in Patients with Symptomatic Degenerative Disc Disease (DDD)

The purpose of this study is to investigate the safety and tolerability of OP-1 when injected into the vertebral disc in the lower lumbar spine.

You may be eligible to participate in this study if you:

• Are between the ages of 18-55 and not of child bearing potential
• Have back and/or buttock pain attributed to degenerative disc disease at a single level
• Have at least 6 weeks of non-surgical treatment

You will be excluded from this study if you:

• Have a herniated disc, compression fracture, or significant spinal stenosis or instability
• Had prior spine surgery
• Have had epidural injections within 6 weeks prior to study treatment
• Have insulin dependent or uncontrolled diabetes, rheumatoid arthritis or MS
• Are involved in litigation related to your spine

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.